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Abstract 
 
 
Oral health of Rheumatoid arthritis patients is an important subject 
which was  investigated by a number of  researchers in different 
countries  and this due to the fact that Periodontitis and rheumatoid 
arthritis have many pathological  features in common and  both 
conditions result from a common  underlying dysregulation of  the 
host  inflammatory response(3)  
The present study could be the first study since the literature did not 
show a similar one in Sudan.It is designed to investigate the 
periodontal status of rheumatoid arthritis patients. 
A group of eighty rheumatoid arthritis patients were selected from 
patients attending the medical department of academic teaching 
hospital,Elribat teaching hospital and Ibrahim Malik teaching 
hospital in the period from January to May 2010 According to the 
following criteria :-  
1- Their age range from 20 – 60 years and diagnosed as rheumatoid 
arthritis patients. 
2- Agreement to participate in the study after signing a written 
concent.  
3- On the other hand patients were excluded according to the 
following criteria:-  aggressive periodontitis or any condition 
that modify the periodontal tissues [e.g DM],smokers, 
Pregnant and lactating females and patients who had previous 
history of periodontal treatment or patients who were used 
antibiotic in the previous three months. 
X 
 
On the other hand eighty healthy individuals with the same age and 
gender collaborated in the study as control group.  
All subjects were examined using the plaque index (PI), the 
gingival  index (GI) , calculus, frequency of oral hygiene habits, 
probeable pocket depth (PPD)and clinical attachment loss (CAL). 
The results revealed that patients with rheumatoid arthritis present 
with same oral hygiene as compared to the control using mean and 
standard deviation(SD) of the   patients (1.25 ± 0.4) while for 
control group the mean and SD was (1.17±0.28)p-value is 
(0.3597).No difference in calculus for patients,mean and SD 
(0.48±0.4) and (0.49±0.44) for the controls p-value(0.9986).Also no 
difference in the gingival index,mean and SD (1.2±0.24) for the 
patients and (1.2 ± 0.33) for the control with p-value ( 0.3049 ) . 
The rheumatoid arthritis patients had   more pocket  depth,mean and 
SD (0.46±0.42) and (0.15±0.22) for control with p-value 0.000 at  
0.05 level of significance .Also increase in attachment loss level in 
rheumatoid arthritis patients, mean and SD (1.03±0.95) and 
(0.56±0.63) for the control with p-value 0.0002. There is no effect 
of the drug used by these rheumatoid arthritis patients on their 
periodontal measurement. From the study there was no relationship 
exist between the disease duration and the periodontal 
measurements.  
The results of this study can be explained by dysregulation of the 
host response of the patients in which there is imbalance between 
pro and anti-inflammatory cytokines which result in this 
destruction. 
XI 
 
Taking into consideration the results of the present investigation it 
is recommended that patients with rheumatoid arthritis should 
receive more professional dental care and periodontal treatment 
.More studies should be performed to see the effect of rheumatoid 
arthritis on periodontal tissues and to study the effect of rheumatoid 
arthritis drugs on the periodontium. 
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  اﻟﻤﺴﺘﺨﻠﺺ  
  
  ﻣﻘﺪﻣﺔ
 
ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﻤﻥ ﺍﻟﻤﻭﺍﻀﻴﻊ ﺍﻟﻬﺎﻤﺔ ﺍﻟﺘﻲ ﺘﻌﺭﺽ ﻟﻬﺎ ﻋـﺩﺩ ﻤـﻥ  ﺼﺤﺔ ﺍﻟﻔﻡ ﻟﺩﻯ ﻤﺭﻀﻰ
ﻥ ﻤﺭﺽ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﻭﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜـﺔ ﺩﻭل ﺍﻟﻌﺎﻟﻡ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻭﻫﺫﺍ ﻴﺭﺠﻊ ﺍﻟﻰ ﺃﺍﻟﺒﺎﺤﺜﻴﻥ ﻓﻲ 
ﻟﻭﺠﻴﺔ ﺤﺩﻭﺙ ﺍﻟﻤـﺭﺽ ﺩﺍﺨـل ﺩﺩ ﻤﻥ ﺍﻟﺨﺼﺎﺌﺹ ﻭﺍﻟﺘﻲ ﻤﻥ ﻀﻤﻨﻬﺎ ﺒﻴﻭﻴﺸﺘﺭﻜﺎﻥ ﻓﻲ ﻋ
ﺩﺓ ﻤﻌﺩل ﺍﻟﻬﺩﻡ ﻓـﻲ ﻤﻤﺎ ﻴﺅﺩﻱ ﻟﺯﻴﺎ ﺍﻟﻤﺼﺎﺤﺏ ﻅﻴﻡ ﺍﻟﻤﻨﺎﻋﻲﺍﻟﺠﺴﻡ ﻭﻋﺩﻡ ﺍﻟﺘﻭﺍﺯﻥ ﻓﻲ ﺍﻟﺘﻨ
ﻓﻘﺩ ﺼﻤﻤﺕ ﻫﺫﻩ  ﺍﻟﺴﻭﺩﺍﻥ ﻤﻥ ﻗﺒلﺫﻩ ﺍﻟﻤﺸﻜﻠﺔ ﻟﻡ ﻴﺘﻡ ﺍﻟﺒﺤﺙ ﻓﻴﻬﺎ ﻓﻰ ﻥ ﻫﻭﺒﻤﺎ ﺃ. ﺍﻻﻨﺴﺠﺔ
  .ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﺍﻟﺩﺭﺍﺴﺔ ﻟﻠﺘﻌﺭﻑ ﻋﻠﻰ ﺤﺎﻟﺔ ﺍﻷﻨﺴﺠﺔ ﺤﻭل ﺍﻟﺴﻨﻴﺔ ﻟﺩﻯ ﻤﺭﻀﻰ
  ﻤﻭﻗﻊ ﺍﻟﺩﺭﺍﺴﺔ
ﻴﻤﻴﺔ ﺍﻟﺘﻌﻠﻴﻤـﻲ، ﻤﺴﺘﺸـﻔﻰ ﻭﻫﻲ ﻤﺴﺘﺸﻔﻰ ﺍﻻﻜﺎﺩ ﺜﻼﺙ ﻤﻥ ﻤﺭﺍﻜﺯ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﺒﺎﻟﺨﺭﻁﻭﻡ
 0102ﺍﺒﺭﺍﻫﻴﻡ ﻤﺎﻟﻙ ﺍﻟﺘﻌﻠﻴﻤﻲ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻨﺎﻴﺭ ﺤﺘﻲ ﻤﺎﻴﻭ  ﺍﻟﺭﺒﺎﻁ ﺍﻟﺘﻌﻠﻴﻤﻲ، ﻤﺴﺘﺸﻔﻰ
  .
  ﻫﺩﺍﻑﺍﻷ
  ﺍﻷﻫﺩﺍﻑ ﺍﻟﻌﺎﻤﺔ
  ﺩﺭﺍﺴﺔ ﺤﺎﻟﺔ ﺍﻟﻠﺜﺔ ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ
  ﺍﻷﻫﺩﺍﻑ ﺍﻷﺨﺭﻯ
ﺒﺤﺎﻟـﺔ   ﺞﻗﻴﺎﺱ ﻤﻌﺩل ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔ ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﻭﻤﻘﺎﺭﻨـﺔ ﺍﻟﻨﺘـﺎﺌ  -
 ﺍﻻﺼﺤﺎﺀ
 ﺼﺤﺔ ﺍﻟﻔﻡ ﻭ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔﻭ  ﻠﻰ ﺍﻟﻌﻼﻗﺔ ﺒﻴﻥ ﻤﺭﺽ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡﺭﻑ ﻋﺍﻟﺘﻌ -
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 ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔ ﻗﻴﺎﺱ ﺍﻟﻌﻼﻗﺔ ﺒﻴﻥ ﻤﺩﺓ ﺍﻟﻤﺭﺽ ﺍﻟﺯﻤﻨﻴﺔ ﻭﻤﻌﺩل -
ﻤﻊ ﺍﻻﺩﻭﻴﺔ ﺍﻟﻤﺴـﺘﺨﺩﻤﺔ ﺍﻟﻌﻼﻗﺔ ﺒﻴﻥ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔ ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ  ﻗﻴﺎﺱ -
 ﻟﻌﻼﺠﻪ
 
  ﻁﺭﻴﻘﺔ ﺍﻟﺒﺤﺙ
ﻭ  ﻋـﺩﺩ  ﻓﻰ ﻫﺫﺍ ﺍﻟﺒﺤـﺙ  ﻭﺍﻓﻕ ﺜﻤﺎﻨﻭﻥ ﻤﺭﻴﻀﺎ ﻤﻥ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ  ﻟﻠﻤﺸﺎﺭﻜﺔﻟﻘﺩ 
ﻟﻜل ﺍﻟﻤﺸﺎﺭﻜﻴﻥ ﻓﻲ ﺍﻟﺒﺤﺙ ﺘﻡ ﺍﻟﻜﺸﻑ . ﻤﻥ ﺍﻻﺼﺤﺎﺀ ﻜﻌﻴﻨﺔ ﻀﺎﺒﻁﺔ ﻟﻬﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺜﻤﺎﻨﻭﻥ
( ssenliS& eoL)ﺤﺎﻟﺔ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔ   eoL dna ssenliS()ﻋﻠﻲ ﺍﻟﻠﻭﻴﺤﺔ ﺍﻟﺠﺭﺜﻭﻤﻴﺔ 
ﻋـﺩﺩ , ﻭل ﺍﻟﺴﻨﻴﺔ ﻨﺴﺠﺔ ﺤﺠﻭﺩ ﺍﻟﺠﻴﺏ ﺍﻟﻠﺜﻭﻱ، ﻭﺠﻭﺩ ﻓﻘﺩﺍﻥ ﺍﻷﻭ, ﻭ ﻋﺩﻤﻪﻭﺠﻭﺩ ﺍﻟﻘﻠﺢ ﺃ
                                                                   .ﺩﺍﺓ ﺍﻟﻤﺴﺘﺨﺩﻤﺔﺍﻙ ﻭﺍﻷﻤﺭﺍﺕ ﺍﻟﺴﻭ
        
  ﺍﻟﻨﺘﺎﺌﺞ
ﻗﺩ ﺃﻭﻀﺤﺕ ﻨﺘﺎﺌﺞ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ  ﺃﻜﺜﺭ  ﺍﺼﺎﺒﺔ ﺒﺎﻨﺘﺎﻨﺎﺕ ﺍﻟﻠﺜﺔ ﺤﻴـﺙ  
ﺍﻟﺠﻴـﺏ ﺍﻟﻠﺜـﻭﻱ  ﺩ ﻗﻴـﺎﺱ ﺍﻟﻤﺘﻭﺴﻁ ﻭﺍﻻﻨﺤﺭﺍﻑ ﺍﻟﻤﻌﻴـﺎﺭﻱ ﻟـﺩﻴﻬﻡ ﻋﻨ  ـ ﺒﻠﻐﺕ ﻗﻴﻤﺘﺎ
ﺍﻟﺩﺍﻟـﺔ  ﻗﻴﻤﺔ ﻭﻜﺎﻨﺕ( )22.0±51.0ﺍﻻﺼﺤﺎﺀ  ﺒﻴﻨﻤﺎ ﺒﻠﻐﺕ ﻗﻴﻤﺘﻬﻤﺎ ﻟﺩﻯ( )24.0±64.0
ﻭﺍﻻﻨﺤـﺭﺍﻑ ﺍﻟﻤﻌﻴـﺎﺭﻱ ﻋـﻥ ﻓﻘـﺩﺍﻥ  ﺍﻟﻤﺘﻭﺴﻁ ﺕ ﻗﻴﻤﺘﺎﺒﻴﻨﻤﺎ ﺒﻠﻐ ، 000.0 ﺍﻻﺤﺼﺎﺌﻴﺔ
 ﺒﺩﺍﻟـﻪ ( 36.0±65.0) ﻭﺍﻷﺼﺤﺎﺀ 59.0±30.1() ﺍﻷﻨﺴﺠﺔ ﺤﻭل ﺍﻟﺴﻨﻴﺔ ﻟﺩﻱ ﺍﻟﻤﺭﻀﻰ
ﻔﻡ ﻭﻭﺠﻭﺩ ﺍﻟﻘﻠـﺢ  ﺒـﻴﻥ ﻟﻟﻡ ﻴﻭﺠﺩ ﻓﺭﻕ ﻤﻥ ﺤﻴﺙ ﺍﻻﻫﺘﻤﺎﻡ ﺒﺼﺤﺔ ﺍ.  2000.0ﺍﺤﺼﺎﺌﻴﺔ 
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ﺔ ﻟﻌﻼﺝ ﺩﻭﻴﺔ ﺍﻟﻤﺴﺘﺨﺩﻤﺭﺓ ﺍﻟﻤﺭﺽ ﺍﻟﺯﻤﻨﻴﺔ ﻭ ﺍﻷﻓﺘ ﺃﻥ ﻜﺫﻟﻙﺘﺒﻴﻥ ﺼﺤﺎﺀ ﻭﺍﻟﻤﺭﻀﻲ ﻭﺍﻷ
  .ﺍﻨﺨﻔﺎﺽ ﻨﺴﺒﺔ ﺍﻨﺘﻨﺎﻨﺎﺕ ﺍﻟﻠﺜﺔ  ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﻟﻡ ﻴﻭﺠﺩ ﻟﻬﺎ ﺃﺜﺭ ﻭﺍﻀﺢ ﻋﻠﻰ
  ﺍﻟﺨﻼﺼﺔ 
ﻟﻡ ﻴﻭﺠﺩ ﻓﺭﻕ ﺒﻴﻥ ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﻭﺍﻻﺼﺤﺎﺀ ﻓﻰ ﻤﻌـﺩل ﻭﺠـﻭﺩ ﺍﻟﻠﻭﻴﺤـﺔ  -
 .ﻭﻋﺩﻤﻪﻭ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻠﺜﺔ ﻭﻭﺠﻭﺩ ﺍﻟﻘﻠﺢ ﺃﺍﻟﺠﺭﺜﻭﻤﻴﺔ 
ﻤﺭﻀﻰ ﺍﻟﺭﻭﻤﺎﺘﻴﺯﻡ ﺃﻜﺜﺭ ﺍﺼﺎﺒﻪ ﺒﺎﻨﺘﺎﻨﺎﺕ ﺍﻟﻠﺜﺔ ﻤﻥ ﺤﻴﺙ ﻭﺠﻭﺩ ﺍﻟﺠﻴﺏ ﺍﻟﻠﺜـﻭﻯ  -
 ﻭﻓﻘﺩﺍﻥ ﺍﻷﻨﺴﺠﺔ ﺤﻭل ﺍﻟﺴﻨﻴﺔ
ﻟﻡ ﻴﻭﺠﺩ ﻓﺭﻕ ﻤﻥ ﺤﻴﺙ ﺍﻻﻫﺘﻤﺎﻡ ﺒﺼﺤﺔ ﺍﻟﻔﻡ ﺒﻴﻥ ﺍﻟﻤﺭﻀﻰ ﻭﺍﻷﺼﺤﺎﺀ ﻤﻤﺎ ﻴـﺩل  -
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction: 
The  oral  cavity  is  thought  as  the  window  to  the  body  because  
oral  manifestation  accompany  many  systemic  diseases.(1) 
Periodontitis is  a common  disease  world wide  that  has  a primary  
bacterial  etiology  and  is  characterized  by  deregulation  of  the  
host  inflammatory response which  eventually  result  in  soft  and  
hard  tissue  destruction  (2,3) . More over the degree of inflammation 
varies among individuals with  periodontal disease, independently 
of the degree of bacterial  infection  suggesting  that  alteration  of  
the  immune  function  may  substantially  contribute  to  its  extent 
(4,5,6) 
Periodontitis is the most prevalent disease affecting bone in human , 
in  the  severe  form  of  the  disease  if  not treated  it  can  lead to 
tooth loss in 10  to 15 % of adults (7).  
Periodontitis is a chronic bacterial infection of the supporting 
structure of the teeth. It is more common in males (8) 
 The host response to periodontitis is important factor to determine 
the extent and severity of disease. 
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On the other hand systemic factors modify periodontitis through 
their effect on normal immune and inflammatory mechanisms, 
several conditions may give rise to increase prevalence incidence or 
severity of gingivitis and periodontitis ( 9 ) ,one of these is RA. 
More recently it has been reported that individuals with 
periodontitis are 4 times more likely to have reported history of 
Rheumatoid arthritis (RA) (10) 
It is  estimated  that arthritis and  other rheumatic conditions  affect   
42.7  million Americans (11) With   prevalence of  0.5 to 1%   in 
Western population(12).It is connective tissue disease with  
prevalence of  1%  in  the  population, most common  in  females 
(13) , affecting  women  3 times  more  than  men (14,15) 
RA has extra-articular manifestation in systems such as  pulmonary, 
oral, ocular, vascular and other organs or structures that may be  
affected by  the inflammatory process (2) In addition to alteration in  
systemic immune function RA is characterized by accumulation   of   
pro-inflammatory  cell infiltrates in the synovial membrane, which 
lead to synovitis, destruction  of  cartilage  and  bone tissue  of  the 
joint and ultimately  to physical impairment  and  disabilities. (15, 16) 
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RA often affects the proximal inter-phalangeal and meta carpo 
phalangeal joints (15), which may lead to substantial manual    
disability due to that oral  hygiene  may  be  impaired  making   
those  people susceptible to inflammatory periodontal diseases 
(12).Another aspect which must not be under estimated is 
represented by the possible therapeutic RA programme, which  
could interfere with  the  pathogenesis of  the  periodontal  disease, 
making the observation of  relationship  between  the  two  diseases 
more   difficult (17) . 
1.2. JUSTIFICATION 
RA is a chronic disabling condition with medical and social 
implications. It is a common disease in Sudan (18).The relationship 
between periodontitis and  RA  have been  examined  only  by  few 
studies  in the last years (2,19)  and  the  literature  correlating  the  
severity of  RA and  the  severity  of  periodontal disease is scant(19). 
Recent studies showed that patients with RA have higher 
prevalence of periodontitis (20, 21). Due to  all  these  fact, this  study  
was designed to  investigate  the  periodontal  status and  its severity 
in RA  patients  and to find  if there is association  between RA and 
periodontal disease among  those  patients in  Khartoum. 
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1.3. OBJECTIVES 
A) General objectives of the study 
To study periodontal status among RA patients. 
B) Specific Objectives of the study 
1- To measure the periodontal parameters of a population of    
diagnosed RA patients in order to compare the results with 
systemically healthy individuals. 
 2- To estimate the degree of association among RA, oral hygiene   
and periodontitis.                     
3- To   measure   the   effect of   disease duration on the periodontal  
        Parameters measurement. 
4-  To  measure periodontal parameters of  RA patients and to 
correlate it to its treatment modalities.  
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1.4. LITERATURE REVIEW 
1.4.1.Periodontal   Diseases 
The normal periodontium consist of  the investing  and  supporting  
tissues of the tooth : -  gingiva , periodontal  ligament, cementum  
and alveolar  bone. It  has been divided into two parts: -First part is 
the gingival part, the main function of it is  protection  of  the 
underlying  tissues and the second part is the attachment apparatus 
part, which is composed of periodontal ligament, cementum , and  
alveolar  bone .  
The cementum  is  considered  a part  of  the  periodontium  because  
with the alveolar bone it serves as support for the fibers of  
periodontal  ligament.The periodontium is subject to morphologic 
and functional variations as well  as changes  associated  with  
age(22) .  
Periodontal disease is a gum  infection caused  by  bacterial  plaque  
[which  is sticky  colorless  film  constantly  formed  on  the  teeth] . 
Bacteria in plaque infect the gum and release toxins that cause 
redness and inflammation.The inflammation  and  the  toxins cause  
destruction  of the tissues that  support  the  teeth  including  bone , 
when this happen the gum separate  from  the teeth  forming  pocket  
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that  become infected . If  plaque is not  removed, it can turn into 
hard  substance called  calculus  or  tartar  in  less  than  2  days . 
1.4.1.1 Classification of periodontal diseases:   
1.4.1.1.1  Gingivitis:-  
This is inflammation of the gingiva which can be acute, sub acute 
or chronic . It can be localized or generalized , papillary, marginal 
or diffuse (23).  
The most common forms of gingivitis are plaque induced gingivitis 
(24). It's  common  clinical  findings  include  erythema, edema , 
tissue  enlargement  and  bleeding . 
Two  forms  of  plaque  induced  gingivitis  have  been  investigated  
a naturally occurring gingivitis and experimental  gingivitis . There 
is specialized form of gingivitis include that associated with 
hormonal changes, medications and with systemic diseases (25) 
The  prevalence of  gingivitis is evident  world wide  for example  
epidemiological  studies  indicates  that more  than  82%  in  USA .  
A significant percentage of adults show signs of gingivitis. 
A similar or higher prevalence of gingivitis is reported for  children  
and  adolescent   in  other  parts  of  the  world (26) . 
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In  general clinical features of gingivitis may be characterized by 
the presence of any of  the following clinical signs:- Redness  and 
sponginess of the gingival tissue, bleeding on  provocation, changes  
in  color and  presence of calculus or plaque  with  no radiographic 
evidence of crestal bone loss(27)   
Gingivitis is classified to:-  
- Plaque induced gingival disease e.g {gingival diseases 
associated with dental plaque only, gingival diseases 
modified by systemic factor, gingival diseases modified by 
drugs and gingival diseases modified by malnutrition} 
- Non plaque induced gingival lesions e.g {igingival diseases 
of specific bacterial origin, gingival diseases of viral origin, 
gingival diseases of fungal origin, gingival diseases of 
genetic origin, gingival manifestation of systemic conditions, 
traumatic lesions, foreign body reaction and not otherwise 
specific}(28).  
 1.4.1.1.2 Chronic Periodontitis:-   
Is  a  condition  result  in  inflammation  within  the  soft  tissues  
surrounding  the  teeth  causing    attachment  and  bone  loss, 
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periodontal pockets and  recession. These changes are diagnosed 
through periodontal examination and dental x- rays for bone loss.  
Chronic periodontitis occur at any age but most common in adults 
(23) .Chronic periodontitis is the most prevalent form of 
periodontitis,it is slowly progressing disease. It may be localized 
when less than 30% of sites demonstrate attachment loss and bone 
loss or generalized when 30% or more demonstrate attachment loss 
and bone loss(29). Periodontitis is differentiated from gingivitis by 
loss of connective tissue attachment of teeth in the presence of 
gingival inflammation (30) ,migration of epithelial attachment along 
the root surface apically and resorption of bone. Disease activity in 
periodontitis range from slow progression of disease over long 
period of time to an acute episode in which loss of attachment 
occurs rapidly in ashort period of disease activity(31) . 
1.4.1.1.3  Aggressive Periodontitis:-  
 Occurs in patients who are other wise in a good health, 
characterized by rapid soft tissue and bone destruction. There are  2  
forms of  aggressive periodontitis:-  
A- Localized   aggressive periodontitis:-         
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Most often occurs near puberty, involves tissue destruction around 
first molar and or front teeth but may involve one or two additional 
teeth.  
B- Generalized aggressive periodontitis:-  
Often affects people under 30 years, but not always,it involve 3 
additional  teeth other than first  molars  and  incisors (23)  
- Periodontitis as a manifestation of systemic disease. 
-Necrotizing periodontal diseases e.g {necrotizing ulcerative 
periodontitis and necrotizing ulcerative gingivitis}. 
- Abscesses of the periodontium e.g { gingival abscess, 
periodontal abscess and pericoronal abscess}. 
- Periodontitis associated with endodontic lesion { endo-perio 
lesion, perio-endo lesion and combined lesion} 
- Developmental or acquired deformities and conditions e.g 
{localized tooth related factors that predispose to plaque 
induced gingival diseases or periodontitis, mucogingival 
deformities and conditions around teeth, mucogingival 
deformities and conditions on edentulous ridges.and occlusal 
trauma}(28). 
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Natural  history  studies  of  periodontal  disease  in  humans  
indicate  the  presence  of  3  distinct  sub populations (32)   
1- No progression of periodontal disease, in which around 10%of 
the population manifest very little or no disease, which is of no 
particular consequence to the dentition. 
2- Moderate progression, affect around 80% of the population and  
representing a very slowly progressing form of disease that  
generally  can  be  easily  managed  via  routine  therapies. 
 3- Rapid progression, affecting approximately 8% of individuals, 
in which extensive periodontal destruction occurs which can be 
difficult to control. 
1.4.1.2 Etiology:- 
 Despite a remarkable diversity of bacteria found in the periodontal 
microbiota only a few species have been associated with 
periodontitis, this include Pgingivalis ,T- forsythia ,    P-intermedia, 
Campylo bacter rectus, Eikenella corrodens, Fusobacterium 
nucleatum, Treponema denticola, Peptostrepto coccus micros and 
Actino bacillus actino mycetes commitant(A.a). (33, 34,35,36,37, 38, 39, 
40,41). Alterations in the host response associated with specific 
periodontal pathogens are clinically evident. Increased  in  serum 
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and gingival crevicular fluid antibody specific to putative pathogen 
(42, 43 ,44, 45 ) including P- gingivalis ,P intermedia ,C rectus, E 
corrodens , F.nucleatum and (A.a) are  evident  in  patients  with  
periodontitis .   
1.4.1.3 The mechanism of disease production:-   
The  periodontal  diseases  are  well  recognized  as classic example  
of chronic inflammatory diseases  resulting  from induction of  the  
host response to the sub gingival biofilm. Gingivitis  is  typically 
characterized as  a  robust inflammatory  response  confined  mainly  
to  the  superficial  gingival connective tissue and is  a relatively 
non specific response to non specific accumulation of dental plaque, 
how  gingivitis progress to periodontitis is  still  unclear(46).  Heijl et 
al were able to convert a confined naturally occurring chronic 
gingivitis into progressive periodontitis in experimental animal by 
placing a silk ligature into the sulcus and tying it around the neck of 
the tooth .This induced ulceration of the sulcular epithelium, a shift 
in the connective tissue population from predominantly plasma cells 
to predominantly polymorphonuclear leukocytes and osteoclastic 
resorption of alveolar crest(47). periodontitis  appear to be a  more  
specific  inflammatory  response to specific periodontal pathogen 
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reside in  the sub gingival  biofilm, the variability in the clinical 
manifestation and the rate of the disease progression is due to 
differences in  the composition  of  the  sub gingival  microbial flora  
as well as factors that modify the host  response to the microbial 
challenge. 
Bacteria are necessary for disease initiation, they  are not  sufficient  
to cause disease progression unless there is an associated  
inflammatory  response  within  susceptible  host (46). 
There are modifying factors that  do not  cause   the  disease  but  
amplify  some disease mechanisms to  make  the  clinical  condition  
more severe (48).It has been reported  that more than 50%  of  the 
variance in several features of chronic periodontitis can be 
explained  by  genetic  factor. (49,50)  
Some  genetic variations (poly morphism) are commonly  found in 
the population and represent mechanism by which  individuals  may  
exhibit variation within  the  range  of  what  is  considered  normal. 
Since cytokines are key  regulators  of  the  inflammatory  response, 
and  are  more  important  in  periodontitis.  
It  is  notable  that  IL-1  poly morphism  associated  with severe  
periodontitis, which is correlated  2  to 4  fold  with  increase  in  
13 
 
IL-1B production. Many investigators have, however demonstrated 
the role of IL-1 in initiation and progression of Periodontitis. IL-1 
 activates the degradation of extra cellular matrix and bones of 
periodontal tissues, elevated tissue or gingival fluid level of IL-1B 
have been associated   with Periodontitis.IL-1 is strong enhancer of 
tissue level of  prostaglandin E2(PGE2) and tumor  necrosis  factor  
alpha(TNF-α) (49 ). Many of  the inter individual variables are 
related to severity of periodontal destruction, and the inflammatory 
responses are attributed partly to amount and  type of  cytokine  that  
individual  produce (51) .More over the HLADR phenotype is not 
particularly strong for periodontitis. There is report indicating that it 
is an important component of genetic susceptibility to some form of 
this disease.  
In addition polymorphisms in the IL-1 beta gene cluster have been 
shown to have a significant correlation with some forms of 
periodontitis in certain populations (52).  
Experimental evidence later emerged to implicate bacterial plaque 
deposits as the primary factor initiating periodontitis. At the same  
time  specific  bacteria and  immune inflammatory  mechanisms  
were implicated  in  the  disease . (53)  
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Current  evidence  seem  to  indicate  that  individuals  predispose 
  to periodontal disease have aberrant immune inflammatory  
responses to plaque which is genetically determined(54).Mechanisms 
responsible could include inappropriate levels of poly morpho 
nuclear cells(PMN) recruitment function or turnover. The resultant 
release of PMN enzymes and reactive oxygen species (ROS) are 
likely to be responsible for tissue destruction. Thus in periodontal 
tissues there is a fine balance between factors determining health or 
disease.  
The first barrier in periodontitis is the epithelial lining of the 
gingival crevice which protects the underlying connective tissue. 
These crevicular and  junctional epithelia are capable of reacting to 
the oral bacteria by releasing signaling molecules which initiate the 
host  response  such  as interlukin-1(IL-1), interleukin -8  (IL-8), 
(PGE2) and granulocyte macrophage colony stimulating factor 
(GM-CSF).These are pivotal in establishing  the early inflammatory 
response through vascular  changes , leukocyte recruitment  and  
activation.  
A  number of  the  putative  periodontal  pathogens  posses  potent 
mechanisms of  evading  or damaging  host  defenses, including  the  
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Following:- 
- Direct damage to poly morph nuclear cells and macrophages 
(MQ).  The  leukotoxins  produced  by  some  strains  of  A.a can  
damage  PMN  and  macrophages.  
A  number  of  bacterial  species  including  P. gingivalis, A.a  and  
capnocytophages  species  can  reduce  PMN  chemo taxis, decrease  
phagocytoses and intercellular killing.(55)A number of gram 
negative black pigmented  anaerobes and  capnocytophages  species 
produce  proteases  which  can  degrade  IgG  and  IgA (56,57,55). 
Cytokines are the major contributing factors of inflammation and 
immune system.There is now growing evidence that infectious 
agents are able to modify cytokines networks to their  
advantage.(59,58) There is also no evidence that some of  the  putative  
periodontal  pathogens  may  have  this  ability . In  this  regard  the  
arginine  specific  tyrosine  like  proteinase  ( RgpA) of  Pgingivalis  
can  both  cleave  and  activate  certain  pro  and  anti inflammatory  
cytokines. (60,61,62)  The balance  between  these  two  opposing  
functions  may  influence  the  inflammatory  status  of  the  local  
cytokine  network  in  periodontal  tissues . It   has  been  shown  
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 that  most  periodontal  pathogens  including  F. nucleatum  and  
A.a  stimulate gingival epithelial cells  to  secrete  IL-8, which  is  
potent  chemo attractant and  activator of PMN  and  intercellular  
adhesion  molecule-1 (ICAM-1) which  is involved  in  leukocyte  
recruitment  from  blood  vessels  into  the  tissues (63,64,65,66) . 
However it  has  been  shown  that  P. gingivalis  stimulation  of  
human  gingival  epithelial  cells  strongly  inhibited  secretion  of 
both  IL-8 and  ICAM-1. (67,65,66) Some  gram  negative  black  
pigmented  an aerobes  posses fibrinolytic  activity.(55)   
Which will reduce the  trapping  of  bacteria  by  fibrin  for  surface  
phagocytosis.  
A number  of  gram negative bacteria  and  spirochetes   in  the  sub 
gingival flora can alter  lymphocyte  function and  produce immune 
suppression.(68) Chronic periodontitis is  characterized  primarily by 
involving alternative pathway activation of  complement with C3  
and C3B cleavage  in gingival  fluid . Pathogen  specific  antibodies  
are formed in chronic periodontitis, activation of classical 
complement pathway by processes involving  antigen  antibody  
binding  does  not  predominate .  P.gingivalis  produce  an  enzyme  
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 that can cleave C5 to its  active  metabolite C5a. Collagenase 
activity is associated with active periodontal  destruction (69).  
MMP-8  is elevated in chronic periodontitis  where  as  the  level  of 
tissue inhibitor of matrix metalloproteinases (TIMP-1) are not. (70)  
New  data  also  suggest  that  the  clinical  characteristic  of  some  
complex  diseases  such  as  periodontal  disease  are  influenced  by  
genetic  and  epigenetic  contribution  to  clinical  phenotype. (71) 
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1.4.2. Rheumatoid Arthritis 
It is typically a persistent, symmetrical, deforming peripheral 
arthropathy, peak onset at the 5th decade of life with a female to 
male ratio of more than 2: 1. Its prevalence is 0.5 to 1%. (72)  
1.4.2.1 Epidemiology 
Rheumatoid arthritis occurs throughout the world and in all ethnic 
groups. The prevalence is lowest in black African and Chinese and 
highest in pima Indians. In Caucasians it is around 1.0 to 1.5%(73), 
prevalence increase with age up from children to elderly. The peak 
onset is between the age of 30 and 35. The prevalence of RA and 
severe crippling deformities to which it often gives rise make it an 
important disorder in group of connective tissue diseases. That RA 
occurs most commonly among females than males is well 
established. The proportion of affected female to affected male is 
about 3 to 1.  It is sometimes postulated that this sex differences in 
the incidence of the disease is based upon hereditary factors, the 
disease may be set in during childhood, adolescence or very early 
adult life. It is most likely to occurs in adults between the 30 and 45 
years of age and occasionally sets in even later life , since the 
disease pursues a chronic course, its overall incidence in given 
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population rises with increasing age of subjects being highest 
among those in sixth and seventh decades.(74) 
A study describing the clinical pattern of RA in Sudan revealed that 
females were the predominant sex with a ratio of female to male of  
9 : 1, one third of the patients [32.45%] in the 6th decade, about one 
third [29.5%] in the 4th decade, half of the patients had a duration of 
illness between 1 and 5 years. Sudanese patients had delayed onset 
of RA. (18)                                 
During the course of pregnancy the subject tend to show clinical 
improvement in respect to her arthritis. It can be conjectured that 
this improvement is the  result of  an inhibitory  factor (possibly 
mediated by hormones) on the immune mechanism  responsible for  
the production of  rheumatoid  factor, however within 4 months  
after childbirth, there is likely to be an exacerbation of arthritic 
manifestation. (75)  
The presentation of rheumatoid arthritis in adults with regards to 
occupation, men engaged in managerial technical occupations and 
in professions have a lower than expected  prevalence of  RA. (76)        
While in elderly the incidence of RA continues to increase past the  
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age of 60. It has been suggested that elderly onset RA may have a 
poor prognosis, more frequent radio logically evident deterioration, 
more frequent systemic involvement and more rapid functional 
decline. 
Severe  disease  is  largely  restricted  to  those  patients with  high 
titre  for  rheumatoid  factor. (77) 
1.4.2.2 ETIOLOGY 
The  cause for  RA  remain  unknown , three  areas  of  interrelated 
researches are currently most promising, these include  host  genetic 
factors, immune regulatory abnormalities and triggering or  
persistent microbial  infection. Genetic susceptibility to RA has 
been clearly demonstrated.  
Certain  major  histocopatibility  complex  MHC CLASS 2  alleles 
and their  encoded  HLA or  human  leukocyte  antigens  occurred  
with increased  frequencies in affected  individuals . Only certain 
HLA subtypes Predispose to RA.Moreover homozygosity for the 
amino acid sequence if carried  on  HLADR4  molecules  has  been  
shown  to correlate with  the disease severity  including  poor  
prognosis  as  manifested  by a more  persistent  disease activity, 
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 destructive joint  disease, Sub cautanous  nodules and  the extra- 
articular  manifestation  especially  rheumatoid  lung  disease and  
Felty's  syndrome. 
The nature of  the  Ag  whether self or  foreign  remain  unknown, 
although candidate include type 2 collagen, proteoglycan,heatshock 
proteins and immunoglobulins. RA appears to be an autoimmune 
disease similar to other MHC class 2 disorders, auto Abs to the Fc 
portion of IgG is present. IgG  molecules or  rheumatoid  factor are  
produced  by T lymphocytes in  the  blood  and the synovial  tissue  
in  80%  of  RA  patients. Such cases are termed  sero positive high 
titers of serum rheumatoid factor typically of  IgM  isotype, when 
detected  by the usual clinical  methods , they are associated with 
more severe joint disease and with extra articular manifestations 
especially subcutaneous  nodules. 
Despite the strong association of rheumatic factor with RA, they 
clearly do not cause the disease. However production of rheumatic 
factor commonly occurs in other disorders in which there is chronic 
antigenic stimulation such as bacterial endocarditis, TB, kalazar, 
syphilis, viral infections, intravenous drug abuse and liver cirrhosis. 
An infectous origin for RA has been a continuous hypothesis 
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(strepto cocci,dephtroid , mycoplasma and clostridium perfrenges) 
have all  been proposed . 
Viral  infection such as  rubella , ros river virus and  more  recently 
barovirus B19 have  been  shown to produce acute poly arthritis but 
no evidence exist that they initiate  chronic RA .  
Also Epstein bar virus remains available but unproved candidate for 
pathogenic role. Ab against nuclear Ag (EBNA) expressed in 
epstien bar virus infected cells occurs in majority of RA patients.(78)   
1.4.2.3 IMMUNOLOGY 
The exact process is still unclear but it is related also to many 
factors that include T cell activation or stimulation of macrophage 
via IgG Fc receptors, other cytokines IL1, IL8, TNF-α granulocyte 
macrophage colony stimulating factor (GMCSf), macrophage 
inflammatory protein (MIP), macrophage chemo attractant protein 
(MCP)and fibroblast IL6. CD4 specific antibodies along with 
bacterial or slow virus infection were implicated. (79) 
Cytokines regulate abroad range of inflammatory processes that are 
implicated in the pathogenesis of RA. In  rheumatoid  joints, it  is 
well known that  an imbalance  between pro- and anti-inflammatory 
cytokine activities favors the induction of autoimmunity, chronic 
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inflammation  and thereby joint damage. However, it  remains  less  
clear how cytokines are organized within hierarchical regulatory 
network.(80).The chronic  synovial  inflammation  may be caused by  
ongoing  T cell  activation or may be maintained by  the  local  
production  of  rheumatoid  factor and continuous stimulation of 
macrophage via IgG  Fc receptors(79) 
CD4 T cell mediate  joint  damage both  directly and by driving  
non  T effecter cells to release inflammatory cytokines and other    
inflammatory associated bone diseases. It operates through a 
common Pathway of accelerated osteoclast recruitment and 
activation. It is now clear that the interaction of receptor activator 
NF-kappa B (RANK) and its legends RANKL play a central role in 
osteoclast formation and activity. 
The success of anti tumor necrosis factor and IL1 therapies  
highlight the central role that these cytokines play in this disease(81)  
The interaction of CD4 T cells with B cells can be driven by the B 
cell to produce IgG  auto antibodies that  may be directly involved   
in   joint damage (82) 
The role that autoimmune processes play in pathogenesis of RA has 
been widely proven. Rheumatoid factor recognize  Fc portion of  
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IgG B cells and  are  able to produce many  important cytokines and  
efficiently present Ag to T-lymphocyte in the synovial  
environment. All these functions are important in  the  development  
of RA (83 ) 
Considering the extent of synovial inflammation and lymphocytic  
infiltration  there are only minimal amount of the  factors  produced  
by T cells (interferon and IL1, IL4 conversly the cytokines 
(IL1,IL8), TNF-α, GMCSF and chemokines produced by  
macrophage (macrophage inflammatory protein)(MIP) and 
monocyte chemo attractant protein (MCP) and fibroblast  
(producing IL6) are abundant, the  relevance of this finding is  
unclear . 
However CD4 specific antibodies when used therapeutically 
produce a specific helper T cell lymphopenia but do not 
significantly alter the disease. Antibodies to TNF-α or specific 
blocking agents  produced marked short term  improvement  in  
synovitis, indicating the pivotal  role of TNF αin chronic synovitis. 
They also reduce the malaise felt in active RA.  
Synovial fibroblast has high level of adhesion molecules, vascular  
cell adhesion molecule (VCAM-1) a molecule which support B 
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lymphocyte survival and differentiation ,also decay  accelerating  
factor (DAF),a factor that  prevent  complement induced  cell  lyses. 
These  molecules may facilitated the formation of ectopic  
lymphoid  tissue  in  synovium. On the other hand  the triggering 
Ag in RA  remains unclear. Although  it is  suggested  that  the 
glycosylation pattern of immunoglobulin may be abnormal in  RA 
and may lead to their becoming potentially antigenic.  
 There is little evidence  that  collagen type 2  is  the  triggering  Ag, 
although it is  a cause  of  arthritis  in  animal  model of RA(79) 
1.4.2.4 PATHOLOGY 
RA is typified by widespread persistent synovitis ( inflammation  of 
the synovial lining of the joint, tendon sheath or bursa).The cause  
of this is unclear but the production of rheumatoid factor by the  
plasma cells in the synovium and the local inflammation of immune 
complexes play a part  in RA.  
The normal synovium becomes greatly thickened to extent that it is 
palpable as boggy swelling around the joint and tendon. There is 
proliferation of the synovium into folds and fronds; also it is 
infiltrated by a variety of inflammatory cells including polymorphs, 
which transit through the tissue into the joint fluid lymphocytes and 
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plasma cells. The normal sparse surface layer of lining cells 
becomes hyper plastic and thickened. There is marked vascular 
proliferation .Increase in the permeability of blood vessels and 
synovial lining layer leads to joint effusions that contains 
lymphocytes and dying polymorphs. Activated lymphocytes and 
macrophage in the synovium produce a rich mixture of cytokines 
including interlukins, prostaglandins and tumor necrosis factor 
alpha. 
The hyper plastic synovium spreads  from  the joint  margins on  to 
  the cartilage surface.This (pannus)of inflamed synovium  damages  
the  underlying  cartilage  by  blocking  its  normal  route  for  
nutrient  and  by  the  direct  effects  of  cytokines  on  the  
chondrocytes . The  cartilage  become  thinned  and  the  underlying  
bone exposed. Local cytokines production and joint disuse  
combine to cause juxta articular osteoporosis during active  
synovitis.  
Fibroblast  from  the  proliferating  synovium  also  grow  along  the  
course of  blood  vessels  between  the  synovial  margins  and  
epipheseal bone  cavity  and  damage  the  bone.This early  damage  
may  justify  the introduction of  disease  modifying  anti  rheumatic  
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drugs  (DMARD) within 3 to 6  months  of  onset  of  arthritis ,Low  
dose  steroids  and  anti tumor necrosis  factor alpha  agents. (84) 
1.4.2.5  Effects of RA on bone:-    
The effects of RA on bone includes structural joint damage  
(erosion) and osteoporosis .The latter may leads to increase risk  for 
fracture which are associated with  increase morbidity and mortality  
The osteoclast cells in RA play a crucial role in development of 
erosions. Peri articular and  generalized osteoporosis  suggested  to 
be mediated through the osteoprotegrin receptor activator of nuclear  
factor(NF k) beta receptor activator of (NF k) beta  ligand  signaling  
system. Based on an improved understanding of this biology new 
treatment opportunities exist.(85) 
Osteopenia associated with RA  is  caused  by the  combined  action  
of prostaglandins and cytokines in  association with normal  amount  
of thyroid hormone .(86) 
Muscle weakness is common symptoms of RA, it  may  have  
several additive causes.Synovial inflammation  is usually associated  
with decrease motion of joints which rapidly produces reflex 
atrophy in muscle bundles  surrounding these  joints, this  effect  is  
most obvious in knees. (87) 
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Focal accumulation  of  lymphocytes  and  plasma  cells  contiguous  
with foci of muscle necrosis  are found in almost all patients with  
RA, this  lesion  called  nodular myositis.   
Some foci of muscle lymphocytes have been shown to synthesize 
IgG rheumatoid factor. (88) 
1.4.2.6  Joint involvement in RA:-                                                 
The effect of RA on  hands  is  severe, in  early  disease  the  fingers  
are swollen, painful and stiff .Inflammed flexor and tendon  sheaths 
increase functional impairment and may cause Carpel Tunnel 
syndrome. Joint damage causes a variety of typical deformities. 
Most  typical  is  the  combination  of  ulnar  drift  and  palmer 
subluxation of meta carpo phalangeal (Mcps), Fixed  flexion  
(button  hole or  boutonniere  deformity ) or  fixed  hyper extension 
(swan neck deformity) of  the  pip joints which impair hand 
function. Swelling  and  dorsal  subluxation of  the  ulnar  styloid  
which  lead to wrist pain and may cause rupture of  the finger 
extensor  tendons, leading  in  turn  to  a sudden  onset  of  finger  
drop  of the  little    and ring  fingers  predominantly. 
RA  commonly affect  the shoulders, Late In the disease rotator  
cuff  tears are  common  and  interfere  with  dressing , feeding  and  
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personal  toilet. Also  synovitis  of the  elbow  causes  swelling  and  
painful  fixed   flexion  deformity . In  late  disease  flexion  may  be  
lost and severe  difficulties with feeding result, especially combined 
with shoulder, hand and  wrist deformities. 
Cervical spine is also affected in RA.Other joints which are affected 
in RA [tempromandibular joint TMJ and sterno synovial joint].(84)  
1.4.2.7 Clinical Manifestations of RA 
At least  3 types of disease manifestation  can be observed  in  RA 
population :  
(1)  Self  limited :  in  these  case  individuals  originally  presented  
RA  have no evidence of  the disease 3 to5 years  later (89). 
(2) Easily controlled disease is easily controlled with NSAIDs (90) 
(3) Progressive disease. These patients generally require second  
line drugs  which  often  still do not fully control  the  disease(91,92)  
1.4 2.8   DIAGNOSIS AND INVESTIGATIONS OF RA  
The diagnosis depends on the clinical features  
The  American  College  Of  Rheumatology ( ACR) criteria  for  
diagnosis  of  RA:   
-  Morning stiffness more than 1 hour [for 6 weeks or more]  
- Arthritis of 3 or more joint [for 6 weeks or more] 
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- Arthritis of hand joints and wrists [for 6 weeks or more] 
- Symmetrical arthritis [for 6 weeks or more] 
- Sub cutaneous nodules  
- A positive serum rheumatoid factor  
- Typical radiological changes [erosions and or peri-articular    
osteopenia] 
  4 or more criteria are necessary for diagnosis of RA 
Initial investigations include:-  
- Blood count: Anemia  may be present  
- Serology 
Rheumatoid factor is present in approximately 70% of cases and 
ANA at low titre in  30%  of  cases . 
- X ray of the affected joint to establish  a base line   
Only soft tissue swelling is seen in early disease  
- MRI: Demonstrates early lesions  
- Aspiration of the joint ,effusion is present  
The aspirate looks cloudy owing to white cells(93)  
1.4.2.9  TREATMENT OF RA  
GENERAL PRINCIPLES: Goals   of therapy are:  
-    To relief pain: Reduction of inflammation 
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-    Protection of articular structures: Maintenance of function. 
-   Control of systemic involvement.  
 Five approaches for medical treatment  
-   Non steroidal anti-inflammatory (NSAID) and cyclo-oxygenase  
(cox2) specific inhibitors (CSIS): Celecoxib , Etodolac , Meloxicam   
and  Rofecoxib. 
- Low dose oral  gluco corticoid : Disease modifying or slow  acting 
    anti  rheumatic  drugs  -DMARD)  
- Tumor necrosis factor alpha necrotizing agent(18) Immuno 
suppressive  and  cytotoxic  drugs. 
 NSAIDS 
They are  so  called  because they  alleviate  pain  by  blocking  the  
formation of inflammatory mediators as do glucocorticoid.  
However NSAIDS lack many of the trouble some side effects of 
corticosteroids.                                                                          
Examples of NSAIDS:- 
Asprin and other salicylates, paracetamol,pyrazolones , mefnamates 
, indomethacin and related drugs. Proprionic acid derivatives  and  
related  drugs                                                  
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Asprin  and  other  NSAID  block the  synthesis  of  prostaglandin 
E2(PGE2) and hence diminish peripheral manifestation  of  tissue  
injury, thus reduce pain, swelling and impaired function of inflamed  
tissue. They exert their action by inhibiting a single step in 
prostaglandin (PG) synthesis by blocking the enzyme cyclo 
oxygenase. Thus cyclin endo peroxide fail to form from arachidonic 
acid. These (PG)are  mediator of  vasodilatation  swelling  and  pain  
in  the inflamed  tissues .   
NSAID Interfere with the mechanisms by which the gastric mucosa 
is protected from its own acid / pepsin secretion, thus the result is 
gastric irritation.                                                                              
CORTICO-STEROIDS:-          
Several mechanisms are  involved  in the  immunosuppressive  and  
anti-inflammatory action of cortico-steroids. Their effects vary with 
dosage which includes:- 
- Intra-cellular  receptor  binding  leads  to  synthesis  or  activation  
of  lipocorin . Lipocorin inhibits phospo-lipase A2 and release of 
arachidonic acid from phospo-lipids.  Synthesis  of  leukotrienes ,   
prostaglandins , thromboxane  and  prostacyclin  is  thus  blocked . 
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- Production of interlukin 2 is depressed by blocking  the  activation  
of interlukin -1 and interlukin 6 genes.T lymphocyte proliferation is 
thus depressed. 
- Lymphokine release and the response to lymphokines are  
diminished .  
- In high doses ,cortico-steroids are cytotoxic to immature T-
lymphocytes  and some of  their  mature  counterparts.  The  overall  
effect  of  cortico- steroids  are  predominantly  Depression  of  cell  
mediated responses and anti-inflammatory action .Antibody  
production and antigen - antibody interaction are not inhibited . The 
glucocorticoids  have  powerful anti -inflammatory and anti-allergic 
action.The mechanism  of  this  effect  is  via  a mediator  substance  
lipocortin . 
The steroid  enters  many  types  of  cells , bind  to  the  cytoplasmic  
receptor and the combination  enter the  nucleus which is stimulated  
to produce the  specific m-RNA for  lipocortin  synthesis .Lipocotin  
mediates  several  actions  which  include :- Inhibition  of  phospho-
lipase and  thus  inhibiting  synthesis of (PG) and leukotrienes . The 
PG cause pain, edema and vasodilatation of acute inflammation.   
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Leukotrienes  mediate  cellular  infiltration, mucosal  secretion  and  
broncho-constriction  in  prolonged  inflammation . 
- Inhibition of production of  interlukin 2 ,this  substance is secreted 
by lymphocytes.  
 Because  steroids  block  proliferation  of  T-cells,by  this  way cell    
mediated  immunity  is  depressed. 
- Inhibition of release and the response to lymphokines  
Lymphokines are proteins released from lymphocytes in severe  
inflammation. Glucocorticoid is used for suppression of 
inflammatory and  immunologically  mediated  diseases  such as 
RA .( 94) 
Although   the  first  line  for  treatment  of  RA  remains  is  
NSAID  . Their  mechanism  of  action is through  the  inhibition  of  
cyclo-oxygenase (COX)  synthesis which  produce  both  analgesic  
and  anti-pyretic  properties .  
While  these  medications  are  effective  in  reduction  of  pain  
symptoms  in  RA , they  do not  significantly  alter  its  course (95) 
Also  the  usage of  NSAID in  the treatment of  periodontal  
diseases  has  been  studied over the past 20 years (96,97,98).While the 
results appear  promising, the  wide spread  clinical  use  of  these  
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medication  to  alter  the  course of Periodontitis has not been 
universal. One particular problem with  their  uses  for  
management  of  Periodontitis  appear  to be a rebound effect  to  
baseline  following  cessation  of  the  medication. (99) With  
discovery  of  two  COX  enzymes  responsible  for  PG  
production,designated COX-1,COX-2,a variety of COX-2 inhibitors 
have been studied for their  potential  to  stop or slow  down  bone  
resorption .  
One of the first COX-2 inhibitor developed is Tenidap. It  inhibit  
not only cyclo-oxygenase and  PG  production  but  also  interlukin-
1, interlukin-6 and tumor necrosis factor alpha  Production . 
To  date  COX-2  inhibitors  have  not  been  thoroughly  studied  
for  their  potential  to  modify  bone  resorption  in  Periodontitis.    
In   contrast   to  the  NSAID  which  do  not  significantly  alter  the  
course of RA , a newer  family  of  medications  designated  disease  
modifying  anti-rheumatic drugs (DMARDs) has been  developed . 
To  be classified  as  DMARD , the  medication  must  demonstrate  
an ability to change the course of  RA  for at least 1 year as evident  
by sustained improvement in function, decreased synovitis and  
prevention of further joint damage(100)Examples of these 
36 
 
medications  include Parentral gold salt,Methiotrexate, 
Sulphasalazine, Hydroxy-chloroquine [ anti-malarial drug ] , 
Pencilliamine, Azathioprine and Leflunomide .A major  drawback  
in the usage of DMARDs is  their  considerable toxicity(101,102).The 
usage of DMARDs for the  management  of  periodontitis  has  been   
largely   restricted  due to  the  toxicity  issues .However  the  usage  
of  Gold  salts  in  animal  model  has  shown  reduced  periodontal  
destruction. (103)  
  Another  emerging  area  for  potential  of  host  modulation  in  
periodontitis  and  RA  is control of  matrix  metallo-proteinases  
(MMPs) which are important  mediator  of  connective  tissue  
breakdown  in  both  soft  and  hard  tissues , in this  regard 
Tetracyclin  and  various  chemical  analogues  have  been  found  
to  inhibit  MMP  activity  by  a mechanism  independent of their  
anti-microbial  property (104,105). A number  of  clinical  trials using 
low dose Tetracycline to modify  periodontitis have  been  carried  
out , with  safety and effectiveness (106,107) .Nonetheless is still 
recommended that  these  data  is interpreted  with caution to 
differentiate between statistically significant and  clinically relevant 
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findings (108)The role of MMP inhibitors in management of RA has 
been less well studied, but promising results are emerging  (109,110,111)          
Control   of  cytokines  and  their  receptors  is  also  emerging  as  a 
field of considerable promise,for example blocking  the  interlukin-
1 receptor antagonist (112,113,114) Similarly  other  studies  have  
shown  that  blocking  the  activity  of another important 
inflammatory cytokines e.g tumor  necrosis factor alpha has 
therapeutic efficacy in RA patients.  (115,116,117,118)              
The  role  of   interlukin-1  and  tumor  necrosis  factor  antagonist  
in a  model  of  periodontitis  have  demonstrated  reduction  in  the 
inflammatory  infiltrate in close  proximity  to  bone  as  well  as 
reduction in the formation of osteoclast and reduced  bone loss. (119)  
Clearly  many  of  this  biologic  agents  which  target  specific  
molecular  events associated with acute and  chronic  inflammation  
have significant potential to alter clinical  outcome for both RA  and  
periodontal  disease.  With the emerging understanding that RA and 
periodontitis are  multifactorial diseases, combination therapies that 
target multiple disease outcome are also emerging.For example in 
animal study it was reported that the administration of a 
combination of  chemically  modified  tetracycline's  ( CMT-1) plus  
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NSAID  such  as flurbiprofen or tenidap  synergistically  inhibited  
severe  bone  destruction  in  arthritis  rats , with  the  suppression  
of MMP activity  in  joints ( 120,121 ) Similar  encouraging  results 
have been  reported  for  periodontitis in  human .( 122) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
1.4.3 The relationship between periodontitis and rheumatoid 
arthritis :- 
In  the  year  1998    a study   made  by   American   Academy  Of  
Periodontology  confirmed  that  mouth  infection  can  cause  major  
problems in other  parts of  the body. Periodontal and gum diseases 
can cause bleeding, discomfort and even tooth loss. Infection can 
eventually enter the blood stream, travel to major organs and begin 
new infections.  
The National Institute Of Dental Research( NIDR) has found strong  
association between   gingival  infection  and   number of  diseases. 
In   addition  to  the  rapidly  growing  recognition  of   the link 
between oral and general health, there is increasing awareness of 
the  potential the mouth hold for assisting in early diagnosis of  
diseases.(123)   
Periodontitis and RA appear to share many pathological features. 
Emerging  evidence now suggests a strong  relationship between  
the extent and severity of  periodontal  disease  and  RA .It  is  clear 
that individuals with advance RA are more likely to  experience  
more  significant  periodontal  problems  compared  to  their  non  
RA  counterparts .These  two diseases could be very  closely related 
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through common underlying dysfunction of fundamental 
inflammatory mechanisms. The nature of such dysfunction is still 
unknown. The clinical implication  of the current  data indicate  that 
patients with RA should screened for their  periodontal status.  (3)  
It must  be  recognized  that  periodontitis differ  in  one  significant  
way from RA, through understanding that the  sub gingival  biofilm   
is a key etiological factor. Unlike periodontal disease no specific 
bacterial etiology has been identified for RA.  
Thus  while  host  modification  of  disease  processes  are  possible  
for periodontitis, controlling the bacteria that cause periodontal  
infections remain a significant  focus for periodontal  treatment  and  
prevention.Best  host modification can be only an adjunct treatment 
for periodontitis. However until  an etiological factor can  be  found  
for RA, host  modification remain  the main stay for treatment. 
There is no question that periodontitis and RA have many 
pathological features in  common. Hence the possibility  exists  that  
both  conditions  result  from  a common underlying deregulation of  
the host inflammatory response. There is accruing evidence  to  
support  the  notion   that  both  conditions  manifest as a result of 
imbalance between pro-inflammatory and anti-inflammatory  
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cytokines. As a result new treatment strategies will emerge for  both  
diseases that may target the inhibition of pro-inflammatory 
cytokines  and destructive proteases.(3) 
To  date  very few studies  have  examined the  association between  
RA and  periodontal  diseases , the  results  have  been  conflicting . 
For example Finish studies found no correlation between 
periodontal disease and arthritis (124) while others (125,126) suggest a 
higher prevalence of bone loss in RA.A major reason for these 
discrepancies  relates  to  the lack of  uniformity  in  classifying  the  
various  forms  of  periodontal  disease  and  RA .  
Indeed  most  of  early  studies ( 125,124,127)  failed  to  take  into  
account  the  various  forms  of  RA  and  periodontal  diseases .In  
a subsequent  study , 65  patients  attending  a rheumatology  clinic  
were  studied  for  their  level  of  periodontitis  and  RA (3) A 
control group  consisted  of  aged  and  gender  matched individuals  
who  did  not  have  RA. No  difference  were  noted  for  plaque  
and  bleeding  indices  between  the  control  and  RA group. The  
RA group did , however  have significantly more missing teeth  
than  the  control  group and  greater  percentage  of  these  subjects  
have deeper  pocketing  compared  to  the controls . The  percentage  
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of alveolar bone loss correlated positively with the principal  
parameters  of  RA  severity. These two pilot studies have resulted 
in several significant findings. RA patients do  not  have  impaired  
oral hygiene (judged by  plaque and bleeding scores) Perhaps  more 
importantly, it was noted that  individuals  with severe RA are more 
likely to have advanced  periodontitis and vice versa. 
Although  many  RA  patients  take  medications  that  can  reduce  
periodontal destruction [NSAID and  immunosuppressant] , there  is  
notable  periodontal  destruction  in  those  patients .This   indicate  
that prior to  the  development  of  RA  symptoms, the  periodontitis  
was not  likely  developing  and not detected. Thus disease  duration  
may be very important factor .Finally in order to understand the 
inter-relationship between periodontitis and  RA, it  is  necessary  to  
categorize the disease on the basis of severity and duration( i.e  type  
of  disease )  
Recently  using  an animal  model, additional evidence has  been   
presented to indicate significant relationship between periodontitis  
and RA (128) From this  study  it was  reported that  inducing  
experimental  arthritis  in  the  rat ( adjuvant  arthritis )  resulted  in 
periodontal  breakdown   characterized  by  alveolar  bone  loss  and  
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increased matrix metallo proteinase (MMP) activity in adjacent  
gingival  tissues . Interestingly all of this reactions occurred without 
manipulating the oral or sub gingival micro-flora. Most recently  
studies have begun to  investigate  the  co-distribution  of  cytokines  
involved in vascular damage and bone resorption  in  biopsies  from  
graded RA and periodontitis lesions.Since the tumor necrosis factor 
like molecules and their receptors have been shown to  be involved  
in  both  processes.   
There was previous study of the  receptor  activator of  n F kappa  B 
legend(RANKL),osteo-pretogren(OPG) and  tumor  necrosis  factor  
related apoptosis including  legends (TRAIL) to determine at least  
one  molecular  mechanism common to  both  conditions. 
The cell  surface  tumor necrosis factor like  molecule (RANKL) 
and  its receptor RANK  have been shown to be key factors  
regulating   osteoclast formation and activation (129,130) It  has  been  
shown that  when  RANKL  binds to RANK on  the surface  of  
osteoclast  precursors , these  cells  differentiate to  form  mature  
osteoclasts.It is now clear that RANKL, together  with  macrophage  
colony stimulating factor( M-CSF) is required for osteoclast  
formation . The  soluble  TNF [receptor  like ] molecule, OPG  is a 
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natural  inhibitor  of  RANKL (131) , OPG  binds to  RANKL  and  
prevent its legation to RANK . The  importance  of  these molecules  
in regulating bone metabolism has been demonstrated by  
transgenic and  gene knock out studies in mice (132) Since these  
factors  regulate  physiologic  osteoclast formation. It  is  reasonable  
to  propose that  they  may  also  be  key  regulators  of pathological  
bone  resorption (133,134). Although RANKL is normally provided  by 
osteoclast like cells in bone.(134, 135) There  are  reports  suggesting  
that  lymphocyte  present  in  rheumatoid  tissue  may be the  main 
source in  inflammatory  arthritis (129,136) Furthermore CD4 T-cells 
from the human rheumatoid joint express RANKL and can promote 
osteoclast formation from rodent spleen precursors (136). In  addition  
to  lymphocytes  production of  RANKL, inhibition of  RANKL  by 
OPG treatment in vivo reduces both bone  and  cartilage destruction  
in  a model  of  adjuvant  arthritis. (137) Under  certain  conditions, 
human osteoclasts precursor cells present in or near the  tissues  of  
arthritic  joints (138,139) 
More recent  reports  in  humans (140,141) and  animals (137 ) show  that 
RANK,RANKL interaction may required for osteoclast formation  
and bone resorption in RA joint .Accordingly  (OPG ) and  RANKL  
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were  expressed  in  biopsies  of  inflamed  rheumatoid  synovium  
and periodontitis lesions.(142) The production of OPG by  endothelial  
cells may be significant for  reasons  other  than  its  effects on bone 
metabolism. There is now evidence to suggest that OPG might also 
regulate endothelial cell function. OPG  has  been  reported  to  be  
required for endothelial  cell  survival and growth(143) , in addition 
OPG knockout mice have been shown to develop arterial  
calcification(144,145)as well as severe osteoporosis, suggesting that 
vascular endothelial expression of OPG may have a role in vascular 
homeostasis(137 ).  In response to pro-inflammatory cytokines tumor 
necrosis factor alpha and interleukin-1β, OPG mRNA expression  
was dramatically enhanced resulting in secretion of newly  
synthesized OPG  and  reduction  of  cell  associated  OPG  .Such  
findings  are  consistent with  the  observation  in  vivo  for  active  
RA  and  periodontitis  lesions. Vascular damage  due to apoptosis  
is  thought  to precede vascular calcification.(144) And contribute to  
atherosclerosis. (147) 
 In  addition  diabetic  endothelial  cell  dysfunction  is  associated  
with  DNA  damage induced  by poly(ADP-ribose) polymerase  
activation. The  exact  cause  of  endothelial  cell  dysfunction  is  
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not  known  but  it  is  possible  that  molecules  such as  TRIAL, 
expressed  in  nearby  cells  and  tissues  , may  be  important.(134,148) 
The recent  finding  studies  confirm  that  OPG  binds  to TRAIL, 
although  with  less  affinity  than  RANKL,in  vitro, and  block  its  
activity (unpublished  data).The  final  piece of  evidence  for the 
role of  OPG  in  vascular  damage  comes from  the  fact  that OPG  
knockout mice  develop vascular calcification . It is  significant  to  
note  that calcification can not  be  reversed  by systemic  treatment  
with recombinant  OPG  post partum. (144) This supports the concept 
that OPG  must  be  expressed  within  endothelial cell, either  in 
appropriate form or associated  with other  molecules, and  this only 
occurs following normal  synthesis  within  the  healthy endothelial  
cells. In light of above, there at  least one underlying common  
molecular  pathway in  common between  RA and  periodontitis  
may lie within RANK, OPG, TRAIL axis  whereby OPG  decreases  
leading  to decrease  in  vascular protection  in  addition with  an 
increase in RANKL and TRAIL within  the  tissues , not  only is 
vascular damage  possible  but  significant  activation of osteoclasts 
may result. The proposal still awaits verification. Most of the 
association between periodontitis and systemic diseases are 
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explained in a part by excessive production of pro-inflammatory 
cytokines and other inflammatory mediators of which 
prostaglandin-E2 (PGE2), TNF-α and IL-6. (18) Periodontitis has a 
remarkably similar path biology to RA. (149) In  both  diseases  
progression consists  of  the  continuing  presence  of  high  levels  
of  pro-inflammatory cytokines. Furthermore,  low  levels  of  tissue  
inhibitors of metalloproteinases (TIMP) and  high  levels of  matrix 
metalloproteinases  (MMP), and  PGE2  secreted  by  macrophages 
, fibroblasts , and  other  resident  and  migrating  inflammatory  
cells  characterize  the  active  stage  of  both  diseases.   
Previous  studies  have  reported  contradicting  findings  on  the  
relationship between periodontitis and RA.(150,151,126,152,153)          
However  in  light  of  the variability  in  both  RA  and  periodontal  
disease classifications, it is difficult to compare these results . More  
recently, it has been reported is that  individuals  with  periodontitis  
are  4  times  more  likely  to  have  a self  reported  history  of  
RA(10). In this RA population, 62.5 had advanced forms of 
periodontal disease. (10) Given the problems with accuracy of self 
reported disease experience, preliminary findings of likely 
relationship between RA and periodontitis.(10) require further 
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validation. A patients would have  greater exposure to NSAID,these 
drugs are well documented to limit  periodontal  bone  loss  when  
taken  long  term. (154 ) The  majority  of  RA  patients  most  likely  
were suffering from an advance form  of  disease , as  they  attended  
a tertiary  referral  clinic. Such  patients  have  usually  passed  the  
level  of  taking NSAID for  disease  control  and  are  often  taking  
a range  of  disease modifying medications. (19 ) 
In humans, many of these genes  which regulate  monocytic  
cytokines  response  have been mapped to HLA – DR  region  of  
chromosome  5 in  the  area  of  the  TNF-β genes. (155,156 ) Both  RA  
and   progressive periodontitis are associated with this HLA  
complex(157,158) .  
This  provides  a common  genetic  basis  for  the  observed  
monocyte  triat, linking  RA, progressive  periodontitis, and  other  
systemic diseases. It is reasonable  to  suggest, therefore, that  inter-
individual  differences  in  the  severity  of  RA  and  periodontal  
disease  are  partly  due  to  intrinsic  differences  in  the monocyte / 
T cell response triats. In  both disease, inflammatory  challenge  to  
the  monocytic / lymphocytic  axis  may  result  in  the secretion of 
excessive pro-inflammatory cytokines and  inflammatory  
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mediators , of  which  PGE2, TNF-α, interlukin 1, interlukin 6  
would  appear  to  dominate.(18) The loss  of  bone  and  other  
connective  tissues  in  periodontitis, as  well  as  in  the  synovial 
joint  with  RA, is  mainly  a consequence of  increased  local  tissue  
destruction , i.e , a  disturbed  balance between tissue formation and  
degradation Cytokines participate  in  the  regulation  of  this  
process (3), the  pro-inflammatory  cytokines  (TNF-α) and  
interlukin-1 beta are  important  promoters  of  bone  resorption  in  
both  diseases, but  there  are  many   other  cytokines  involved, 
such  as  interlukin-6. 
This  cytokine  increases  the  number  of  osteoclast(157) and  is  a 
promoter of PGE2 synthesis and release; this, in turn, promotes  
osteoclast  fusion  and  blocks  bone  formation. (159 ) leading  to  
bone loss. The amount of resulting bone resorption depends on the 
tissue  concentration of  different  resorptive  promoters and on  the  
presence  of  cytokine  inhibitors such  as  the  receptor  antagonist  
of  interlukin-1(IL-ira) (3,159 ) TNF-α  is  often  present  at  the  site 
of  inflammation , as  well  as  in  the  circulation , and  is  believed 
to be responsible for the modulation of systemic inflammation (160 ) 
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The  circulating  TNF-α is  mainly  derived  from  local  release  by  
macrophage  and  T- cells  in  inflammatory  joint  lesions. (161) As 
well as from circulating peripheral mononuclear cells. High levels  
of  TNF-α  in  plasma  are  associated  with  radiographic  signs  of  
tem- promandibular  joint (TMJ) bone  tissue  degradation  in  
patients  with  RA. (162,163 ) It  has been  suggested  that  TNF-α  is  
an important  factor  in  periodontitis  progression and that it 
participates in periodontal  tissue  destruction  by  stimulating  the  
production  of  MMP. (164)  TNF  activity  is  considered  of  major  
pathologic  importance  in  periodontitis  and  RA (165), and  
inhibition  of  TNF  with  biologic  antagonists  has  been  
successful. (66.167.168.169) 
There  are  several  systemic  markers  of  inflammation  such  as  
C-reactive protein (CRP),erythrocyte sedimentation rate (ESR), 
rheumatoid factor (RF) and thrombocyte particle concentration 
(TPC). TPC is increased as a result of  thrombocytosis that occurred 
within a few days  after the  inhibition  of  inflammation, and 
thrombocytes are  activated  by  RF  to  release  serotonin (5-HT). 
Increase periodontal attachment loss and deeper periodontal  
pockets have been found in patients with RA and juvenile  
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idiopathic  arthritis with  increased  levels  of  RF, CRP and  
ESR.(18,170,171) 
Although Mikael et al in 2008  carried  an investigation  in  Sweden  
to study the association  between  the  circulating  pro-inflammatory  
mediators TNF-α, PGE2, interlukin–1beta,serotonin,rheumatoid  
factor  and  periodontitis in patients with  RA . The  results  of  the  
study  suggested  that  in  patients  with  RA , high  plasma  levels  
of  TNF-α  were  related  to  gingival  bleeding  on  probing , more 
attachment loss, and deeper pockets compared  to  those  with  low  
plasma  levels. 
These findings also suggest  that  the  inflammatory  process  in  the  
periodontal tissues is related to circulating  TNF-α with  regard  to 
tissue destruction (periodontitis) and vascular reactions (gingivitis). 
The  plasma  level  of TNF-α,  which  is  associated  with  the  
degree  of  systemic  inflammation (CRP)  may  influence  the  
development  of  periodontitis  in  patients  with  RA. RF, PGE2, 
interlukin-1 β and serotonin  in plasma did not  contribute  
significantly  to  the  variation  in the  periodontal  variables  in  this  
study which  could  be due to sample  size  as  well  as  low  plasma  
level  of PGE2  and interlukin-1 β detected . (172) 
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Also F.B.Mercado  et  al  in  2001  in  Australia  carried  a study  on  
a population  of  RA  patients  ( 65  patient ) The  results  show  no  
differences for  plaque  and  bleeding  indices  between  the  control  
and  RA  group . RA  group  have  more  missing  teeth  than  the  
control  group and  higher  percentage  of  deeper  pocketing. (18)  
And  N.Pischon  et  al  in  2008 in  Germany study 57  subjects  
with RA  and 52  healthy  control. The  results  show  that  subjects 
with  RA have significantly  increased  periodontal  attachment  loss 
compared  to control. Oral hygiene may only partially account for 
this association.(12) 
Astudy by YANIV. M  et  al  in  2009   in  Haifa Israel, the   result 
of the  study  show  that  RA  patients  receiving  anti TNF-α  
medications  have  lower  periodontal  indices  and  GCF TNF-α 
level, thus  suppression  of  pro – inflammatory  cytokines  might  
prove  benefit  in  suppressing  periodontal  diseases . Also  data  
shows  that RA  patients  exhibit  overall  worth  periodontal  and  
gingival  condition .(173) 
Although Gleissner . C  et  al(174)  in  1998  in  Germany studied 50  
RA  patients  matched  with  101  healthy  control . The results 
show no correlation between the duration of pharmacotherapy and 
53 
 
the periodontal parameters. Patients  with  long  term  active  RA  
present  higher  degree of periodontal  disease  including  loss  of  
teeth  compared  with  controls. Functional impairment of upper 
extremity might amplify present periodontal disease. The  long  
term  use  of  NSAID , corticosteroids and  DMARD  show  no  
connection  with  the  severe  periodontal  disease  observed  in  this  
patients, oral  hygiene  amplify  periodontal  disease  severity  and  
treatment  need. Intensive  prophylactic measures are required  to  
prevent  or  reduce  the  damage  of  periodontal  tissues  in  RA.   
And  Ka"sser UR  et  al  in  1998  in  Germany   carried  a  study  in  
50  RA  patients  and  101  healthy  control.  The  results  of  the  
study  concluded  that  patients  with  longstanding  active  RA  
have  a substantially  increased  frequency  of  periodontal  disease, 
including loss of teeth, compared with  controls. Anti-inflammatory  
treatment interferes with  periodontal  disease  and  might  have  
masked a possible correlation  between  the  indices of chronic  
destruction  in  RA  and  periodontal  disease. (125) 
Also  Ishi  Edi P  et  al  in 2008  in  Brazil  carried  a study [in39 
RA  patients  and  22  healthy  individuals] The  results  of  the  
study  show  that RA had fewer teeth ,higher  prevalence of  sites  
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presenting  dental  plaque  and   a  higher  frequency  of  sites  with  
advanced attachment  loss. Based on above results, there is an 
association between periodontal disease and RA .(175) 
A study  in  Brasil  in  2005  is  carried  by  Ribeiro J  et  al.  The  
study  is  done  in  42  patients , they  were  classified  into 2 groups 
Group 1 submitted  to  oral  hygiene  instruction  and  professional  
tooth cleaning ,while group  2 had  full  mouth  scaling  and  root 
planning. The result suggested  that periodontal  treatment with 
scaling and root might have an effect on  erythrocyte  sedimentation 
rate  reduction. (176) 
A study   in  USA  in   2007  is  carried  by  Al-Katma. 29  subjects  
diagnosed with  RA  participate  in the study, the  results  concluded 
that control  of  periodontal  infection  and  gingival  inflammation  
by  scaling/ root planning  and  plaque  control  in  subjects  with  
periodontal  disease  may  reduce  the  severity  of  RA .(177) 
And study by Ortiz P  et  al  in  2009  in  Cleveland , in  40  patients  
with  moderate  to  severe  RA, the  results  concluded  that  non  
surgical  periodontal  therapy  had  a beneficial  effect  on  the  
signs  and  symptoms  of  RA  regardless  of  the  medications  used   
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to treat this condition, anti TNF-α  therapy  without  periodontal  
treatment had no significant effect on the periodontal  condition.(178)  
Also Ezel  Berker  in  Turkey  in  the  year 2000 , carried  a study  
in  45  patients, concluded  that  in  patients  with  RA medication  
including corticosteroid and NSAID may decrease gingival 
inflammation, but the synthesis and degradation of IL-6 in  gingival  
tissue  of  RA  patients  may  be  different. The  study  was  the  first  
report  determining  GCF IL-6 Level in  RA  patients.(179 ) 
De  Pablo   in  USA  in  2008  In  the results  RA  may  be  
associated  with  tooth  loss  and  periodontitis. (180) 
A study in France by Pers JO in 40 subjects with RA, the result was   
TNF–α, blockade could be beneficial in the treatment of 
periodontitis. (181) 
Basak et al in 2009 carried a study in Turkey in 74 subjects. The 
results showed  that  gingival  crevicular  fluid  MMP – 8  level  
increased  with periodontal inflammation despite  the  long  term  
usage of cortico-steroid and NSAID, similar  gingival  crevicular 
fluid MMP-8  and  13  levels in patients with RA and systemically 
healthy individuals suggest that RA may create a tendancy to 
overproduce these enzyme (182). 
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1.5  Material and Methods 
1.5.1  Study design: 
This is a case control study. 
1.5.2  Sample size: 
160 cases [80 case groups and 80 control group].  
1.5.3  Study population:  
1.5.3.1  Study group     
Eighty Rheumatoid  arthritis  patients (RA)  aged  20 –60  years old 
was examined  from the common  rheumatoid  arthritis clinics  in  
Khartoum  State . 
1.5.3.2  Control group:  
Eighty non RA healthy individuals were examined as a control 
group.  
Those were selected from Co-patients, employee in the same 
centers, the patients and the control group was matched in relation 
to gender and age.    
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 1.5.4  Inclusion criteria: 
1.5.4.1  Study group: 
- Diagnosed patients with RA (20–60 years old) with consideration 
of  the disease duration.   
- Willingness of the patient to participate in the study                    
-  Only partially or fully dentate patients(at least 8 teeth excluding 
3rd molar)  
1.5.4.2  Control group: 
- Age group 20 – 60 years old  
- Absence of rheumatoid arthritis 
- Willingness to participate in the study 
- Only partially or fully dentate patients(at least 8teeth excluding 3rd 
molar) 
1.5.5  Exclusion criteria: 
- Pregnancy 
- Lactation 
- Aggressive Periodontitis 
-Previous history of periodontal therapy. 
- Use of antibiotic during the  last  3 months  prior  to  examination. 
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- Any Conditions that modify the periodontal tissue status [e.g. 
D.M].  
-  Smoking and smokeless tobacco 
 1.5.6  General information: 
-Following  approval of the  study plan by the  faculty of   Dentistry  
university of  Khartoum  Research  Board , a letter  was sent  to  the  
administrative  authorities of  the rheumatoid  arthritis  clinics with 
a copy of the written consent .After the approval, calibration with 
the supervisor was done to reduce the intra and inter examiner  error  
using Kappa test. All participants in the study signed a written 
consent after explanation of the examination aim to be performed. 
On the other hand Personal data including oral Hygiene tool, 
periodontal chart and information regarding RA was recorded. 
Also potential Risk factors for periodontitis was assessed for both  
patients and control this include socioeconomic status and  
education.                                                                                      
1.5.7  Examination:-                                                                  
- Oral examination for periodontal indexes was performed for 
patients and control group using dental mirror and graduated 
periodontal probe (Michigan"s O).  
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The participant in the study group were examined lying on the 
coaches of the rheumatology clinics. These rheumatology centers 
has good ceiling, lightning,artificial light beside the patient was 
used for additional illumination. The examination was performed 
by one examiner (candidate) with a dentist to record the reading. A 
septic techniques including proper instrument sterilization, usage of 
masks and disposable gloves were done in examination of all 
patients. All teeth was examined at four sites (mesiobuccal–
distobuccal),  (mesio Lingual–distolingual) for presence of plaque 
using the plaque index (PI)(183), for gingival inflammation using the 
gingival index(GI)(184) and calculus also was recorded on the basis of 
present or absent (185). Probing depth was recorded as the distance 
from the free gingival margin to the bottom of the sulcus or 
periodontal pocket. Clinical attachment loss was recorded as the 
distance from cemento-enamel junction to the bottom of the sulcus 
or periodontal pocket. Data was recorded in a special form 
(Appendix 1). 
1.5.8  Statistical Analysis:- 
Standard descriptive statistical techniques was used to summarize 
and present sample information. To check  for  possible  significant  
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differences  in  periodontal  status  between  the  case  and  control  
group, t-test  was used   for normally   distributed data,  in  the case  
of  non-normal  data  Mann-Whitney  test  was used. The data was 
processed using STATA software package(version10). Logistic 
regression was used to assess the effects of  periodontal  parameters 
on periodontal  status  in  the  case  and  control  groups.  
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Results 
 
The data of this study was collected over a period of five months 
from three common rheumatoid arthritis centers in Khartoum . The 
results revealed that the distribution between cases and controls are 
equal in calculus with mean and standard deviation(0.48±0.4) for 
patients and (0.49±0.44) for the controls p-value is 0.9986 at 0.05 
level of significances by using Mann-Whitney test for continuous 
variables and p-value 0.631 by using chi-square test for categorical 
variables (figure-1).                                           
The distribution between cases and controls are equal in plaque 
index with mean and standard deviation(SD) (1.25 ± 0.4) for 
patients while the control group was (1.17±0.28) p-value is 0.3597 
at 0.05 level of significance by using Mann- Whitney test for 
continuous variables and p-value 0.524 by using chi- square  test for 
categorical variables (figure-2). Also the distribution between cases 
and  controls are equal in gingival inflammation with mean and 
standard deviation (1.2±0.24) for the patients and (1.2 ± 0.33) for 
the control p-value is 0.3049 at 0.05 level of significance by using 
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Mann- Whitney test for continuous variables and p-value 0.049 by 
using chi- square test for categorical variables  (figure-3).                                      
For probeable pocket depth the distribution between cases and 
controls are not equal rheumatoid arthritis patients had  more pocket  
depth with mean and standard deviation (0.46±0.42) and 
(0.15±0.22) for control  p-value is 0 at 0.05 level of significance by  
using Mann - Whitney test for continuous variables and p-value 0 
by using chi- square   test for categorical variables (table-1).                                  
Also the distribution between cases and controls are not equal in 
clinical attachment loss, increase in attachment loss level in 
rheumatoid arthritis patients with mean and standard deviation 
(1.03±0.95) and (0.56±0.63) for the control  p-value is 0.0002 at 
0.05 level of significance by using Mann-Whitney test for 
continuous variables and p-value 0.006 by using chi- square test for 
categorical variables (table-2).                                      
From the study there is no significant correlation between duration 
of illness and plaque index (p-value0.9786), gingival index (p-value 
0.9079),probeable pocket depth (p-value0.5978) and clinical 
attachment loss ( p-value 0.0933) at 0.05 level of significance 
(table-10). 
63 
 
The results of differences between case and control in oral hygiene 
habits showed that there is no association between frequency of oral 
hygiene between case & control variable at significant level 0.05(p-
value is  0.262).There is no association  between frequency of oral 
hygiene and gingival index at significant level 0.05(p-value 0.752). 
And no association (independent) between frequency of oral 
hygiene and plaque index at significant level 0.05 (p-value 
0.852)(table-3,4,5).There is association between gingival index and 
plaque index at significant level 0.05 (p-value 0.048) (table-6,7). 
This  study had showed that  no association exist between the drugs 
used to treat  rheumatoid  arthritis (NSAIDs  & DMARDs ) and  the 
periodontal  parameters  ( plaque index , gingival index , probeable 
pocket depth and clinical  attachment loss ) (table-9).                                             
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Table (1):- 
Comparison of the probeable pocket depth (per millimeters) 
between case and control:- 
 
 
 Cases 
(N=80) 
Controls 
(N=80) 
P 
Value* 
≤0.5 
>0.5 to ≤ 1 
>1 to≤1.5 
>1.5 
52 (65%) 
20 (25%) 
5 (6.25%) 
3 (3.75%) 
77 (96.25%) 
2 (2.5%) 
1 (1.25%) 
0 (0%) 
0.000 
Mean± SD 0.46± 0.42 0.15± 0.22 0.000 
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Table (2):- 
Comparison of clinical attachment loss(per millimeters) 
between case and control:- 
 
 
  Cases 
(N=80) 
Controls 
(N=80) 
P 
Value* 
≤1.17 
>1.17 to ≤ 2.33 
>2.33 to≤3.5 
>3.5 
52 (65%) 
20 (25%) 
5 (6.25%) 
3 (3.75%) 
70 (87.5%) 
7 (8.75%) 
3 (3.75%) 
0 (0%) 
0.006 
          
Mean± SD 
    
1.03± 0.95 
    
0.56± 0.63 
            
0.0002 
66 
 
Table(3):-  
The association of oral hygiene and Periodontitis for the study 
group:- 
 
 Case & Control 
variable 
Gingival Index Plaque Index 
Frequency of 
oral hygiene 
 
NA                    
p-value (0.262) 
NA 
p-value (0.752) 
NA 
p-value (0.852) 
 
 
 
 
*NA  :-  No association 
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Table (4) :- 
The independency between frequency of oral hygiene and  
gingival index among cases using chi-square test:- 
 
 None Once per 
day 
More than 
two times 
per day 
Total 
 >0.64 to < 1.09 
>1.09 to < 1.54 
>1.54 
28 
42 
6 
1 
1 
0 
1 
0 
0 
30 
43 
6 
Total 76 2 1 79 
 
P- value = 0.752 
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Table (5) :- 
The independency between frequency of oral hygiene and 
plaque index among  cases using chi-square test:- 
 
 None Once per 
day 
More than 
two times 
per day 
Total 
<0.99 
>0.99 to < 1.63 
>1.63 to < 2.27 
>2.27 
8 
57 
10 
1 
0 
1 
1 
0 
0 
1 
0 
0 
8 
59 
11 
1 
Total 76 2 1 79 
 
P- value = 0.852 
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Table (6) :-  
The independency between gingival index and plaque index 
among cases using chi-square test:- 
 
 >0.64 to <1.09 >1.09 to<1.54 >1.54 Total 
<0.99 
>0.99 to < 1.63 
>1.63 to < 2.27 
>2.27 
5 
24 
1 
1 
3 
33 
7 
0 
0 
3 
3 
0 
8 
60 
11 
1 
Total 31 43 6 80 
 
P- value = 0.048 
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Table (7) :-                                                                                      
The association of plaque index and gingival index in the study  
group:- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Plaque Index 
Gingival Index
P Value 
Association 
(0.048) 
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Table (8) :- 
The number of patients in relation to type of drug used :- 
 
DRUG  TYPE NUMBER OF PATIENTS 
NSAIDs 21 
STEROIDS 44 
*METHIOTREXATE 51 
*HYDROXYCHLOROQUINE 35 
*SULPHASALAZINE 12 
*PENICILLIAMINE 2 
 
*DMARDs:- Disease modifying anti-rheumatic drugs 
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 Table (9):- 
 Association between RA drugs and periodontal parameters:- 
 
 Plaque Index Gingival 
Index 
Probeable 
Pocket 
Depth 
Clinical 
Attachment 
Depth 
NSAIDs 
P Value 
NA  (0.718) NA  (0.343) NA  (0.228) NA  (0.674) 
Steroids 
P Value 
NA  (0.812) NA  (0.932) NA  (0.747) NA  (0.981) 
Pencilliamine 
P Value 
NA  (0.288) NA  (0.198) NA  (0.776) NA  (0.776) 
Methiotrxate 
P Value 
NA  (0.738) NA  (0.415) NA  (0.301) NA  (0.483) 
Hydroxychloroquirie 
P Value 
NA  (0.192) NA  (0.254) NA  (0.563) NA  (0.563) 
Sulphasalazine 
P Value 
NA  (0.944) NA  (0.569) NA  (0.837) NA  (0.590) 
 
? NA  :-     no association  
? P-value  is measured by chi-square test 
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Table (10) :-  
Relationship between duration of illness and periodontal 
parameters:- 
 
 
Duration of 
illness 
Plaque Index  p-value (0.9786) 
Gingival Index  p-value (0.9079) 
Probeable Pocket 
Depth 
 p-value (0.5978) 
Clinical 
Attachment Loss 
 p-value (0.0933) 
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Figure (1):- 
Comparison of the amount of calculus between case and 
control:- 
 
 
 
 
 
  
  
  
  
  
  
  
  
 
 
 
0
.1
.2
.3
.4
.5
m
ea
n 
of
 c
al
cu
lu
s
case control
75 
 
 
Figure (2) :-  
Comparison of the plaque index(PI) between case and control :- 
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Figure (3) :-  
Comparison of the gingival index (GI) between case and  
control :- 
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Discussion 
 
The relationship between RA and periodontitis was attracted the 
attention of health authorities in different countries since 1998(123). 
The ratio of  females to male in this study is 9 : 1 (Appendix-
2).This ratio is greater than the previous studies in other countries 
which reported that females was three time more to develop RA 
than males. 
The association between RA and periodontal disease has been 
examined   only in a few studies with inconsistent results(3). 
Although most earlier studies did not find positive associations of 
RA with periodontal disease(123), more recent evidence(3) showed 
that subjects with RA have higher parameters of periodontal disease 
as compared to non-diseased individuals which is in agreement with 
our results. 
The results of this study provide further evidence that a relationship 
exist between disease experiences of periodontitis and RA . 
The data indicates that individuals with RA are more likely to 
experience more significant periodontitis compared to non 
rheumatoid arthritis patients and vice versa(3). 
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In this study a sample of eighty rheumatoid arthritis patients were. 
selected randomly from three common rheumatoid arthritis clinics 
in Khartoum. Patient aged 20 – 60 were included in the study, on 
the other hand eighty healthy individuals matched with age and sex 
were selected as a control group from co-patients and employee in 
these centers. 
The duration of the disease was recorded but no significant 
correlation  was found when it is compared with clinical parameters 
used PI (p- value is 0.9786), GI (p- value is 0.9079) PPD (p-value is 
0.5978), CAL (p-value is 0.0933).  
On the otherhand the distribution of calculus between cases and 
controls are equal at  significant level of  0.05 by using Man- 
Whitney  test (p-value is 0.9986) and by using Chi-square test(p-
value is 0.631). The literature did not show the difference in the 
calculus amount between study and control group. 
 
It was found that the study group showed no difference in the 
amount of  plaque as compared to the control group (p- value is 
0.524) at significant level of  0.05, this agree with F.B Mercado et 
al (2001) and Yaniv et al (2009) .The observation in our study is 
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consistent with previous other  studies. Thus the general concept 
that RA patients tend to had more plaque deposits because of 
limited dexterity was not validated. 
The results disagree with Ishi et al (2008) who found high 
prevalence of sites with dental plaque (p-value 0.0006) and Ezel et 
al (2000).This may be explained by the fact that those patients 
directed their attention mainly to their serious illness, neglecting 
their oral health.  
The distribution between cases and controls was equal in the 
gingival index (p-value is 0.3049) at significant level of 0.05.  
This agree with  Mercado et al (2001) and Ishi et al (2008).From the 
similar plaque index  and  gingival index of the 2 groups we could 
say that the amount of  destruction seen in the RA group could be 
attributed to other factors. It also disagree with Yaniv et al (2009) 
who found high prevalence of site  with gingival inflammation in 
the RA patients than the control group. 
Inspite of finding of Yaniv 2009  that there is no difference in the 
plaque score  between the patients and the control, the difference in 
the gingival score  indicate that it may be related to the imbalance 
of the inflammatory  nature of the disease. 
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The observation that there was no significant differences in the  
percentage of sites with plaque deposits and gingival inflammation 
is inconsistent with other studies . Thus Rheumatoid arthritis 
patients do not have impaired oral hygiene (judged by plaque and 
bleeding score) 
Regarding he distribution between the cases and controls in the 
probeable pocket depth were not equal i.e (p-value is 0  The mean 
pocket depth >4mm observed in 10% for cases versus 1.25%  for 
controls which indicates presence of deeper pocket depth in the RA 
patients.  
These results agree with Mercado et al (2001), Mikael et al (2008), 
N pischon et al (2008) and Yniv et al (2009). 
The distribution between the cases and controls are not equal in 
clinical attachment level (p-value is  0.002 with mean CAL > 4mm 
is 10% for cases versus 3.75% for controls  which indicates more 
clinical attachment loss of tissues in the RA patients. The results 
agree with Ishi et al (2008), N.Pischon et al (2008),Mikael et al 
(2008) and Depablo et al (2008). Both diseases are  characterized 
by increased secretion of pro-inflammatory mediators, which may 
explain why we found an association of RA  with periodontal  
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disease, even with similarity of oral hygiene between the cases and  
controls. 
In this study, there was no association between frequency of  oral  
hygiene habits between the cases and controls (p-value is 0.262) at 
significant  level of 0.05,the association between frequency of oral 
hygiene and gingival index is not significant (p-value is 0.752) at 
significant level of  0.05,no association is found between frequency 
of oral hygiene and plaque index(p-value is 0.852) at 0.05 level of 
significance and the association between gingival index  and plaque 
index is (p-value 0.048) at 0.05 level of significance. 
Above results indicates no differences between the cases and 
control in oral hygiene habits, So the cause of periodontal 
destruction is related to other  factor rather than poor oral hygiene 
which is in consistency with the previous studies. 
This study had showed that no association between the drug used to 
treat rheumatoid arthritis (NSAIDs & DMARDs) and the 
periodontal parameters (plaque index, gingival index, pocket depth 
and clinical  attachment loss). This agree with findings of Gleissner 
et al (1998) who  found no correlation between the duration of 
pharmacotherapy and the  periodontal parameters Also he noticed 
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that the long term usage of NSAIDs, corticosteroids and DMARDs 
show no connection with the severe periodontal disease observed in 
these patients, but they found that  NSAIDs had a higher rate of 
gingival bleeding (increase by50%), greater probing depth 
(increased by26%) and greater attachment loss (increased  by 73%) 
compared with controls. Anti-inflammatory treatment was observed 
to interfere with periodontal disease and might mask possible 
correlation between the indices of chronic destruction in rheumatoid 
arthritis and periodontitis (121). 
Our results not agree with Ezel et al (2000) who found that 
medication include NSAIDs and corticosteroids may decrease 
gingival inflammation. 
The cause of significant periodontal destruction in rheumatoid 
arthritis  patients despite the usage of drugs(immunosuppressant 
and NSAIDs) may be that prior to development of rheumatoid 
arthritis symptoms the periodontitis was most likely developing and 
not detected, thus the  disease duration may be a very important 
factor. 
In conclusion patients with rheumatoid arthritis show similar 
frequency of brushing, calculus amount , plaque accumulation and 
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similar degree of gingival inflammation on the other hand more 
sites with periodontal pocket and attachment loss than control 
group. 
The findings should be given considerable attention by the medical 
professionals in charge of these patients, and dentist should be 
involved in the general care of rheumatoid arthritis patients in spite 
of their serious problem in order to avoid further deterioration of 
their condition in the future. 
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CONCLUSION 
 
• Rheumatoid arthritis patients show similar plaque index, 
gingival index and amount of calculus to the healthy controls 
matched with age and sex. 
• Periodontal disease is more prevalent among rheumatoid 
arthritis patients as presented in the form of deep pockets and 
clinical attachment level. 
• The oral hygiene of rheumatoid arthritis patients show  
similarity to the healthy subjects which indicate that the cause 
of  periodontal destruction in these patients is related to other 
factor  rather than poor oral hygiene which may be the 
dysregulation of the host inflammatory response. 
• There is no effect of drugs used in the treatment of rheumatoid 
arthritis on the periodontal measurement in spite the possibility 
that the drugs may mask the possible correlation between the 
two diseases. 
• There is no effect of the disease duration on the periodontal 
measurement. 
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Recommendations 
 
 
• Periodontal status of Rheumatoid arthritis patients should be 
carefully screened. 
• All Rheumatoid arthritis patients should receive supportive 
periodontal treatment at regular interval and this should be a 
part of their overall health care to prevent further deterioration 
of their condition in the future 
•  The need for a close collaboration among physicians, dentists, 
and dental hygienists when treating patients with RA.  
• A need for further researches to be conducted in the future. 
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APPENDIX 1 
Examination    Sheet 
 
 
RESULTS ANSWER QUESTION 
    Code number
    Location
  1 male                           2 female Sex
    Age
  1 single         2 married         3 widow  
  4 divorce 
Marital status
    Residence
    Occupation
  1 high           2 moderate           3 low Level of education
  1 high            2 moderate          3 low Housing level
  1good            2 medium            3 low  Socioeconomic status
    Age of disease onset
   Duration of illness
  1 every 3 months        2 every 6 months  
3 yearly 
Frequency of attack
112 
 
  0 no                             1 yes  Disease  control
    Drug type
  0 no                             1 yes NSAIDs
  0 no                             1 yes Steroids
  0 no                             1 yes Pencilliamine
  0 no                             1 yes Methiotrxate
  0 no                             1 yes Hydroxychloroquine
  0 no                             1 yes Sulphasalazine
  0 no                             1 yes Gold salts
  0 no                             1 yes  Others 
  0 no                             1 yes  Is treatment 
compliant 
  0 none                    1 tooth brush  
3 musuak               4 others  
Oral  hygiene tools 
  0 none      1 once per day     2 twice per 
day    3 more than two times per day  
Frequency of oral 
hygiene 
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Calculus 
0 No calculus present  
1  If only supra gingival calculus is presen 
2  If supra and sub gingival calculus is present 
  
according  to  Silliness  and  Lo"e *   (PI)   -Plaque  index: 
0   No plaque    
1  plaque  visible  only  by  probe  or  disclosing  agent    
  2   moderate accumulation of plaque seen by naked eye 
3    heavy  accumulation  of  soft  material  in the  gingival  margin   
  
  
28 27 26 25 24 23 22 21 11 12 13 14 15 16 17 18 
                
                
38 37 36 35 34 33 32 31 41 42 43 44 45 46 47 48 
28 27 26 25 24 23 22 21 11 12 13 14 15 16 17 18 
                
                
38 37 36 35 34 33 32 31 41 42 43 44 45 46 47 48 
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according  to  lo"e (GI)    -GINGIVAL   INDEX : 
0 normal   gingiva  
1 mild  inflammation , slight  change  in  color  , edema  and  no  
bleeding on  probing  
2 moderate inflammation and bleeding on probing     
3 severe  inflammation , ulceration , and  tendency  to  spontaneous 
 bleeding .  
  
  
28 27 26 25 24 23 22 21 11 12 13 14 15 16 17 18 
                
                
38 37 36 35 34 33 32 31 41 42 43 44 45 46 47 48 
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PROBING   DEPTH :- ( PD)  
 
Was  defined  as  the  distance  from  free  gingival  margin  to  the  
bottom  of  the  sulcus  or  periodontal  pocket .  
 
 
CLINICAL  ATTACHMENT  LOSS :- (CAL) 
Is  the distance  from cemento enamel  junction to  the  bottom  of  
the  sulcus  or  periodontal  pocket . 
 
Figure (4): 
282726 25 24 2322211112131415 16 17 18 
                
                
383736 35 34 3332314142434445 46 47 48 
28 27 26 25 24 23 22 21 11 12 13 14 15 16 17 18 
                                
                                
38 37 36 35 34 33 32 31 41 42 43 44 45 46 47 48 
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APPENDIX 2                                                             
The proportion of male and female in the study group:- 
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 3 XIDNEPPA
 ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
  
  اﻟﺪراﺳﺎت اﻟﻌﻠﻴﺎ –ﺟﺎﻣﻌﺔ اﻟﺨﺮﻃﻮم 
  آﻠﻴﺔ ﻃﺐ اﻻﺳﻨﺎن
  
  إﻗﺮار ﻣﺮﻳﺾ
  
ﺗﻘﻮم  اﻟﺪآﺘﻮرة  ﺻﻔﺎء  آﺎﻣﻞ  ﻋﺒﺪ اﻟﺴﻼم  ﺑﺎﺟﺮاء  ﺑﺤﺜﺎ  ﻋﻠﻤﻴﺎ  ﻟﺪراﺳﺔ  
اﻟﻠﺜﺔ  ﻟﺪى  ﻣﺮﺿﻰ  اﻟﺮوﻣﺎﺗﻴﺰم  ﻟﻨﻴﻞ درﺟﺔ اﻟﻤﺎﺟﺴﺘﻴﺮ  و اﺳﻬﺎﻣﺎ  ﻣﻨﻜﻢ  ﻓﻰ   اﻣﺮاض 
ﺎﻟﻤﺸﺎرآﺔ ﻧﺮﺟﻮ  ﻣﻦ  ﺳﻴﺎدﺗﻜﻢ  اﻟﺘﻜﺮم   ﺑﺎﻟﻤﻮاﻓﻘﺔ  ﻋﻠﻰ اﻟﻤﺸﺎرآﺔ  دﻋﻢ  اﻟﺒﺤﻮث   اﻟﻌﻠﻤﻴﺔ  ﺑ
  ﻋﻠﻤﺎ  ﺑﺎن  ﺑﻴﺎﻧﺎت اﻟﺒﺤﺚ  ﺗﺸﻤﻞ  ﻣﻞء  اﺳﺘﺒﻴﺎن  و آﺸﻒ  ﺳﺮﻳﺮى -ﻓﻰ  هﺬا  اﻟﺒﺤﺚ
وﺳﻮف ﻟﻦ ﺗﺴﺘﺨﺪم هﺬﻩ  - ﻟﻼﺳﻨﺎن  ﻋﺎدي  و ﻟﻴﺲ هﻨﺎﻟﻚ اي اﺛﺎر ﺟﺎﻧﺒﻴﺔ ﻣﺘﺮﺗﺒﺔ ﻋﻠﻲ ذﻟﻚ
  -اﻟﺒﻴﺎﻧﺎت ﻟﻐﻴﺮأﻏﺮاض اﻟﺒﺤﺚ
  
  ﻜﺮ  واﻟﺘﻘﺪﻳﺮوﻟﻜﻢ  ﻓﺎﺋﻖ  اﻟﺸ
  
  
 ------------------------------------------- اﻻﺳﻢ
                                      ---------------------اﻟﺘﻮﻗﻴﻊ
  
 ------------------- -: EDOC
